Final results of a phase I study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor receptors (VEGFR), in combination with carboplatin (C) plus paclitaxel (T) in patients with advanced non-small cell lung cancer (NSCLC): A study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG).

Authors

Laurie SA; Arnold A; Gauthier I; Chen E; Goss G; Ellis P; Shepherd FA; Matthews S; Robertson J; Seymour L

pp. 134S-134S

AMER SOC CLINICAL ONCOLOGY

June 20, 2006

42nd Annual Meeting of the American-Society-of-Clinical-Oncology

Atlanta, GA

June 2, 2006

June 6, 2006

JOURNAL OF CLINICAL ONCOLOGY

0732-183X

Andrew Arnold